ReviewFrontiers in endocrinology2026
The liver-brain axis, from its function to preventive therapeutic strategies in diseases.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The liver-brain axis (LBA) represents a bidirectional communication network between the liver and the central nervous system (CNS), governed by integrated neural, humoral, and immune signaling pathways. Emerging evidence indicates that the liver functions not merely as a passive metabolic organ subordinate to central commands, but rather as a dynamic hub that actively senses and modulates peripheral neuroimmune responses. We here first delineate the fundamental communication mechanisms and the transport kinetics of signaling molecules governing LBA interactions. We then examine the profound species-specific disparities between humans and mice-particularly regarding signaling mediators, blood-brain barrier (BBB) architecture, and the hepatic immune microenvironment. From a pathophysiological perspective, we establish that LBA dysfunction serves as a core driver of obesity, diabetes, and their multisystemic sequelae, including cardiovascular diseases and psychiatric disorders such as anxiety and depression. Finally, we highlight recent therapeutic advances targeting the LBA for the management of metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-associated steatohepatitis (MASH), atherosclerosis, and associated psychiatric conditions, thereby underscoring the immense clinical potential of LBA-targeted interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.